Pancreatic cancer: State-of-the-art care

Ca-A Cancer Journal for Clinicians

Volumn 50, Issue 4, 2000, Pages 241-268

  Lillemoe, Keith D ^a   Yeo, Charles J ^a   Cameron, John L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; ANTINEOPLASTIC AGENT; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CYCLINE; DEVAZEPIDE; DNA; DNA BINDING PROTEIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; FLUOROURACIL; FOLINIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; GEMCITABINE; GENE PRODUCT; GUANOSINE TRIPHOSPHATASE; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; PACLITAXEL; PERILLYL ALCOHOL; PROTEIN P16; PROTEIN P53; RECOMBINANT DNA; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA;

AGE; ARTICLE; ASPIRATION BIOPSY; BASE MISPAIRING; BILE DUCT OBSTRUCTION; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA REPAIR; EARLY DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; GENE THERAPY; HISTOPATHOLOGY; HUMAN; JAUNDICE; LABORATORY DIAGNOSIS; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE K RAS; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERCUTANEOUS TRANSHEPATIC CHOLANGIOGRAPHY; PRIORITY JOURNAL; RISK FACTOR; SURGICAL TECHNIQUE; TUMOR SUPPRESSOR GENE; ULTRASOUND;

EID: 0033837021     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.50.4.241     Document Type: Article

References (150)

1. Cancer statistics, 2000
2. The National Cancer Data Base report on pancreatic cancer
3. Recent cancer trends in the United States
4. Epidemiology of and risk factors for pancreatic cancer
5. Genetics of pancreatic cancer. From genes to families
6. Medical history, diet and pancreatic cancer
7. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis
8. Early precursors of pancreatic cancer in college men
9. Pancreatitis and the risk of pancreatic cancer
10. The risk of pancreatic cancer following pancreatitis: An association due to confounding?
11. Epidemiology of and risk factors for pancreatic cancer
12. Nutrition and pancreatic cancer
13. Tumors of the exocrine pancreas
14. Cystic tumors of the pancreas. New clinical, radiologic, and pathologic observations in 67 patients
15. Spectrum of cystic tumors of the pancreas
16. Pancreatic lymphoma. Is surgery mandatory for diagnosis or treatment?
17. Pathology of cancer of the pancreas
18. Molecular biology and the diagnosis and treatment of adenocarcinoma of the pancreas
19. DPC4, a candidate tumor-suppressor gene at human chromosome 18q21.1
20. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia
21. Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+
22. Role of growth factors in pancreatic cancer
23. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival
24. Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer
25. Pain is not a prominent symptom in most patients with early pancreas cancer
26. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial
27. Newonset diabetes mellitus as harbinger of pancreatic carcinoma. A case report and literature review
28. Pancreatic carcinoma as cause of unexplained pancreatitis: Report of ten cases
29. CA19-9 in pancreatic cancer
30. Recurrent pancreatic adenocarcinoma: Spiral CT evaluation following the Whipple procedure
31. CT and MR evaluation of pancreatic cancer
32. Preoperative percutaneous transhepatic internal drainage in obstructive jaundice: A randomized controlled trial examining renal function
33. Does preoperative percutaneous biliary drainage reduce operative risk or increase hospital cost?
34. Evaluation of preoperative biliary drainage in the surgical management of pancreatic head carcinoma
35. A preoperative biliary stent is associated with increased complications after pancreatoduodenectomy
36. Positive intraoperative bile cultures at the time of pancreaticoduodenectomy are associated with preoperative biliary drainage and subsequent development of postoperative infectious complications and mortality
37. How accurate is fineneedle biopsy in malignant neoplasia of the pancreas?
38. Fine needle aspiration cytology of the pancreas
39. Malignant seeding of the tract after thin-needle aspiration biopsy
40. Rapid intra-abdominal spread of pancreatic cancer. Influence of multiple operative biopsy procedures
41. Implications of peritoneal cytology for staging of early pancreatic cancer
42. CT arterial portography vs pancreatic arteriography in the assessment of vascular involvement in pancreatic and periampullary tumors
43. Is preoperative angiography useful in patients with periampullary tumors?
44. Preoperative visceral angiography alters intraoperative strategy during the Whipple procedure
45. Endoscopic ultrasonography in the differential diagnosis of pancreatic disease
46. Endoscopic ultrasound in pancreatic tumor diagnosis
47. Endosonography-guided fine-needle aspiration biopsy: Diagnostic accuracy and complication assessment
48. Staging of pancreatic and ampullary carcinoma by endoscopic ultrasonography. Comparison with conventional sonography, computed tomography, and angiography
49. Pancreatic tumors: Evaluation with endoscopic US, CT and MR imaging
50. Computed tomographic characteristics of pancreatic carcinoma: An analysis of 100 cases
51. Laparoscopy in the staging and planning of therapy for pancreatic cancer
52. Further experience with laparoscopy and peritoneal cytology in the staging for pancreatic cancer
53. Pancreatic cancer. Laparoscopic staging and peritoneal cytology
54. Significance of peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreatic head
55. Preoperative staging and assessment of resectability of pancreatic cancer
56. Survival in 1001 patients with carcinoma of the pancreas
57. Treatment of carcinoma of the ampulla of Vater
58. The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma
59. Adenocarcinoma of the pancreas: A statistical analysis of biliary bypass vs Whipple resection in good risk patients
60. Cancer of the pancreas. 50 years of surgery
61. Decreased morbidity and mortality after pancreatoduodenectomy
62. Pyloric and gastric preserving pancratic resection. Experience with 87 patients
63. Improved hospital morbidity, mortality, and survival after the Whipple procedure
64. Survival after pancreatico-duodenectomy. 118 consecutive resections without an operative mortality
65. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality
66. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients
67. Standards for pancreatic resection in the 1990s
68. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications, outcomes
69. The current status of the Whipple operation for periampullary carcinoma
70. Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence
71. Carcinoma of the periampullary region: Who benefits from portal vein resection?
72. Portal vein resection for pancreatic adenocarcinoma
73. Reliability and sensitivity of frozen-section pancreatic biopsy
74. The use of operative sonography in carcinoma of the pancreas
75. Preservation of the pylorus in pancreaticoduodenectomy
76. Pylorus-preserving pancreatoduodenectomy. A clinical and physiologic appraisal
77. Pylorus-preserving pancreatectomy: Functional results
78. A comparison of long-term results of the standard Whipple procedure and the pylorus preserving pancreatoduodenectomy
79. Pancreatoduodenectomy with pylorus preservation for adenocarcinoma of the head of the pancreas
80. Pylorus-preserving pancreatoduodenectomy. Is it an adequate cancer operation?
81. Total pancreatectomy
82. Further evaluation of total pancreatectomy
83. Total pancreatectomy for cancer. An appraisal of 65 cases
84. Histopathology in the evaluation of total pancreatectomy for ductal carcinoma
85. Total pancreatectomy for ductal adenocarcinoma of the pancreas. Mayo Clinic experience
86. Radical pancreatectomy
87. Regional pancreatectomy for cancer of the pancreas, ampulla, and other related sites. Tumor staging and results
88. Practical usefulness of lymphatic and connective tissue clearance for the carcinoma of the pancreas head
89. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas
90. Surgical indication and significance of portal vein resection in biliary and pancreatic cancer
91. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: A multicenter, prospective, randomized study
92. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy
93. Carcinoma of the body and tail of the pancreas
94. Carcinoma of the body and tail of the pancreas: Is curative resection justified?
95. Management of adenocarcinoma of the body and tail of the pancreas
96. Radical pancreatoduodenectomy: A 22-year experience with complications, mortality rate, and survival rate
97. Pancreatoduodenectomy: A retrospective review 1949-1969
98. Factors influencing morbidity and mortality in pancreatico-duodenectomy
99. The effects of regionalization on cost and outcome for one general high-risk surgical procedure
100. Importance of hospital volume in the surgical management of pancreatic cancer
101. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy
102. Should pancreaticoduodenectomy be performed in octogenarians?
103. Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results
104. Short-term administration of SMS 201-995 in the management of an external pancreatic fistula
105. Role of octreotide in the prevention of postoperative complications following pancreatic resection
106. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery
107. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: A prospective, controlled, randomized clinical trial
108. Delayed gastric emptying after pylorus-preserving pancreaticoduodenectomy
109. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized placebo-controlled trial
110. Periampullary tumors: Which ones should be resected?
111. Current trends in the diagnosis and treatment of carcinoma of the pancreas
112. Prognostic indicators for survival after resection of pancreatic adenocarcinoma
113. Carcinoma of the pancreas: Review of MGH experience from 1963-1973. Analysis of surgical failure and implications for radiation therapy
114. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection
115. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
116. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience
117. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum
118. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas
119. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas
120. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas
121. Surgical palliation for pancreatic cancer. The UCLA experience
122. Surgical management of unresectable carcinoma of the pancreas
123. Prospective controlled trial of transhepatic biliary endoprosthesis versus bypass surgery for incurable carcinoma of head of pancreas
124. Endoscopic biliary endoprosthesis in the palliation of malignant obstruction of the distal common bile duct: A randomized trial
125. Randomised trial of endoscopic endoprosthesis versus operative bypass in malignant obstructive jaundice
126. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice
127. Palliative operations for pancreatic carcinoma
128. Evaluation of palliative surgical procedures in unresectable pancreatic cancer
129. Current status of surgical palliation of periampullary carcinoma
130. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s
131. Biliary stent occlusion-a problem solved with self expanding stents?
132. A prospective, randomized clinical investigation of cholecystoenterostomy and choledochoenterostomy
133. Surgical palliation for pancreatic cancer: Developments during the past two decades
134. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial
135. Management of pain in pancreatic cancer
136. Pain management of pancreatic carcinoma: A review
137. Neurolytic celiac plexus block for pancreatic cancer pain
138. Guidelines for the application of surgery and endoprostheses in the palliation of obstructive jaundice in advanced cancer of the pancreas
139. Pancreaticoduodenectomy: Does it have a role in the palliation of pancreatic cancer?
140. Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas
141. Radiosensitization of pancreatic cancer cells by 2',2'-difluoro-2'-deoxycytidine
142. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas
143. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas and papilla of Vater
144. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer
145. Development and characterization of cytokinesecreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
146. Current management of pancreatic carcinoma
147. The pancreas
148. Palliative therapy for pancreatic cancer